drugset / Trial / NCT02626234

A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors

NCT02626234

Phase 1 Completed 32 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

the study aim to assess the effect of INC280 on the pharmacokinetics of digoxin and rosuvastatin in patients with cMET-dysregulated advanced solid tumors

Timeline

Start
2015-12-08
Primary completion
2017-02-28
Completion
2017-04-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Capmatinib Small molecule
Subject Digoxin Other / unclassified
Subject Rosuvastatin Small molecule

Indications

No indication recorded.